Targeting pentamidine towards CD44-overexpressing cells using hyaluronated lipid-polymer hybrid nanoparticles
Drug Delivery and Translational Research · 2024
DOI: 10.1007/s13346-024-01617-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2024. Verfasst von Ilaria Andreana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino, Torino, Italy. Hauptthemen laut MEDLINE: Hyaluronic Acid, Polylactic Acid-Polyglycolic Acid Copolymer, Hyaluronan Receptors, Nanoparticles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Biodegradable nanocarriers possess enormous potential for use as drug delivery systems that can accomplish controlled and targeted drug release, and a wide range of nanosystems have been reported for the treatment and/or diagnosis of various diseases and disorders. Of the various nanocarriers currently available, liposomes and polymer nanoparticles have been extensively studied and some formulations have already reached the market. However, a combination of properties to create a single hybrid system can give these carriers significant advantages, such as improvement in encapsulation efficacy, higher stability, and active targeting towards specific cells or tissues, over lipid or polymer-based platforms. To this aim, this work presents the formulation of poly(lactic-co-glycolic) acid (PLGA) nanoparticles in the presence of a hyaluronic acid (HA)-phospholipid conjugate (HA-DPPE), which was used to anchor HA onto the nanoparticle surface and therefore create an actively targeted hybrid nanosystem. Furthermore, ionic interactions have been proposed for drug encapsulation, leading us to select the free base form of pentamidine (PTM-B) as the model drug. We herein report the preparation of hybrid nanocarriers that were loaded via ion-pairing between the negatively charged PLGA and HA and the positively charged PTM-B, demonstrating an improved loading capacity compared to PLGA-based nanoparticles. The nanocarriers displayed a size of below 150 nm, a negative zeta potential of -35 mV, a core-shell internal arrangement and high encapsulation efficiency (90%). Finally, the ability to be taken up and exert preferential and receptor-mediated cytotoxicity on cancer cells that overexpress the HA specific receptor (CD44) has been evaluated. Competition assays supported the hypothesis that PLGA/HA-DPPE nanoparticles deliver their cargo within cells in a CD44-dependent manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino, Torino, Italy.
- Dipartimento di Oncologia, Università di Torino, Torino, Italy.
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università di Milano, Milano, Italy.
- Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino, Torino, Italy. barbara.stella@unito.it.
ORCID-Profile: Barbara Stella
Zitieren
APA
Andreana, I., Chiapasco, M., Bincoletto, V., Digiovanni, S., Manzoli, M., Ricci, C., Del Favero, E., Riganti, C., Arpicco, S., & Stella, B. (2024). Targeting pentamidine towards CD44-overexpressing cells using hyaluronated lipid-polymer hybrid nanoparticles. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01617-7
Vancouver
Andreana I, Chiapasco M, Bincoletto V, Digiovanni S, Manzoli M, Ricci C, et al. Targeting pentamidine towards CD44-overexpressing cells using hyaluronated lipid-polymer hybrid nanoparticles. Drug Delivery and Translational Research. 2024. doi:10.1007/s13346-024-01617-7
BibTeX
@article{Andreana2024,
author = {Andreana, Ilaria and Chiapasco, Marta and Bincoletto, Valeria and Digiovanni, Sabrina and Manzoli, Maela and Ricci, Caterina and Del Favero, Elena and Riganti, Chiara and Arpicco, Silvia and Stella, Barbara},
title = {Targeting pentamidine towards CD44-overexpressing cells using hyaluronated lipid-polymer hybrid nanoparticles},
journal = {Drug Delivery and Translational Research},
year = {2024},
doi = {10.1007/s13346-024-01617-7}
}
EUVIMED